Veeva Systems Unveils Clinical Trials Study Start-Up Solution

November 3, 2015

Company News Release

Top 20 pharma and top 10 global CRO sign on as first Veeva Vault Study Start-Up customers

PHILADELPHIA, PA - Nov. 2, 2015 - At the Veeva 2015 R&D Summit today, Veeva Systems announced the first fully integrated clinical trials study start-up solution. Veeva Vault Study Start-Up will enable life sciences organizations to manage both the content and the activities associated with activating sites for clinical trials. This comprehensive solution will accelerate time to first patient enrollment, automate manual processes, and deliver seamless interoperability with the electronic trial master file (eTMF) for a single, reliable source of all trial-related content.

Life sciences organizations have made strides in adopting advanced solutions to increase speed and efficiency in many areas of the trial process. According to the 2015 TMF Reference Model Survey, the majority of respondents (61%) are either using or actively planning on using an eTMF. And, according to the Veeva 2015 Paperless TMF Survey, speeding study start-up is cited by 56% of the respondents as a top driver of eTMF application adoption in their organizations.

“The life sciences industry has long struggled with manual and inefficient processes for study start-up,” said Kathryn King, vice president of Vault Clinical at Veeva. “Existing solutions managed either documents or start-up activities, but never both together. This created significant challenges in identifying and addressing issues during start-up, resulting in longer study durations and impacting overall time to market.”
 
Traditional solutions exacerbated the problem by focusing on either site start-up documentation or site initiation data, but were unable to bring the documents and data together. Further, these systems were often disconnected from the eTMF applications that also needed the information as part of the trial’s history. The fragmented landscape contributed to lengthy site initiation timelines, a process that, on average, takes 17 months to complete, according to research from the Tufts Center for the Study of Drug Development.
 
“Sponsors and CROs have typically used unsophisticated, disparate, and incompatible proprietary and customized approaches to manage study start-up and initiation activities,” said Ken Getz, associate professor at CSDD Tufts University School of Medicine. “This has contributed to the historically high level of inefficiency and inconsistency that we’ve observed in investigative site engagement and activation.”
 
Vault Study Start-Up will bring together site start-up documents and initiation in a single solution, while providing seamless interoperability with Veeva Vault eTMF. This combination of capabilities will ensure a single source of truth for all start-up related content and data. Sites, sponsors, and CROs will be able to access the same clinical information, simplifying collaboration and increasing efficiency. Vault Study Start-Up will also provide advanced capabilities to better manage start-up processes, including a complete, reliable electronic audit trail.
 
Vault Study Start-Up will be available in early December 2015. A top 20 pharmaceutical company and a top 10 global CRO have already signed on as early Vault Study Start-Up customers.
 
In other news, Veeva Vault RIM was also announced today at the 2015 Veeva R&D Summit. Vault RIM is a next-generation regulatory information management suite that unites submission documents, published dossiers, product registrations, and agency commitments into a single authoritative source for the global organization.
 

Related Content:

News